Studies have shown that CD38 can enhance adenosine (ADO) content in the tumor microenvironment to promote tumor metastasis and inhibit CD8+ T cell function while inhibiting CD38 or blocking ADO receptors can effectively improve the efficacy of targeted immune checkpoint therapy [166, 168]. Here, CD38 is linked to neoplasm.